1. Home
  2. DNTH vs MMI Comparison

DNTH vs MMI Comparison

Compare DNTH & MMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DNTH
  • MMI
  • Stock Information
  • Founded
  • DNTH 2015
  • MMI 1971
  • Country
  • DNTH United States
  • MMI United States
  • Employees
  • DNTH N/A
  • MMI N/A
  • Industry
  • DNTH Biotechnology: Pharmaceutical Preparations
  • MMI Real Estate
  • Sector
  • DNTH Health Care
  • MMI Finance
  • Exchange
  • DNTH Nasdaq
  • MMI Nasdaq
  • Market Cap
  • DNTH 1.4B
  • MMI 1.2B
  • IPO Year
  • DNTH N/A
  • MMI 2013
  • Fundamental
  • Price
  • DNTH $33.67
  • MMI $30.45
  • Analyst Decision
  • DNTH Strong Buy
  • MMI Sell
  • Analyst Count
  • DNTH 11
  • MMI 2
  • Target Price
  • DNTH $65.22
  • MMI $29.00
  • AVG Volume (30 Days)
  • DNTH 516.1K
  • MMI 130.6K
  • Earning Date
  • DNTH 11-07-2025
  • MMI 11-07-2025
  • Dividend Yield
  • DNTH N/A
  • MMI 1.70%
  • EPS Growth
  • DNTH N/A
  • MMI N/A
  • EPS
  • DNTH N/A
  • MMI N/A
  • Revenue
  • DNTH $4,854,000.00
  • MMI $725,903,000.00
  • Revenue This Year
  • DNTH N/A
  • MMI $9.50
  • Revenue Next Year
  • DNTH N/A
  • MMI $17.73
  • P/E Ratio
  • DNTH N/A
  • MMI N/A
  • Revenue Growth
  • DNTH 17.87
  • MMI 17.89
  • 52 Week Low
  • DNTH $13.37
  • MMI $27.35
  • 52 Week High
  • DNTH $40.16
  • MMI $42.80
  • Technical
  • Relative Strength Index (RSI)
  • DNTH 46.99
  • MMI 55.70
  • Support Level
  • DNTH $32.28
  • MMI $28.59
  • Resistance Level
  • DNTH $35.40
  • MMI $31.73
  • Average True Range (ATR)
  • DNTH 1.59
  • MMI 0.87
  • MACD
  • DNTH -0.20
  • MMI 0.06
  • Stochastic Oscillator
  • DNTH 26.53
  • MMI 59.24

About DNTH Dianthus Therapeutics Inc.

Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.

About MMI Marcus & Millichap Inc.

Marcus & Millichap Inc is a national brokerage firm specializing in commercial real estate investment sales, financing, research, and advisory services. The company offers three primary services to its clients: commercial real estate investment brokerage, financing, and ancillary services, including other research, advisory, and consulting services. The company generates revenues by collecting fees on the sale and financing of commercial properties. These fees consist of commissions collected upon the sale of a property and fees collected from the placement of loans.

Share on Social Networks: